Antithrombin I. Inhibition of thrombin generation in plasma by fibrin formation

Thrombosis and Haemostasis

Volumn 89, Issue 1, 2003, Pages 9-12

  Mosesson, Michael W ^a  

^a BLOOD RESEARCH INSTITUTE   (United States)

Author keywords

Antithrombin; Fibrin; Thrombin; Thrombin inhibition

Indexed keywords

ANTITHROMBIN; ANTITHROMBIN I; DIMER; FIBRIN; FIBRINOGEN; FIBRINOGEN VARIANT; FIBRINOPEPTIDE; PLASMA PROTEIN; THROMBIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

AFIBRINOGENEMIA; BINDING AFFINITY; BINDING SITE; BLOOD CLOTTING; CARBOXY TERMINAL SEQUENCE; FIBRIN FORMATION; FIBRINOGEN BLOOD LEVEL; FIBROGENESIS; HUMAN; INHIBITION KINETICS; NONHUMAN; PATHOGENESIS; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN DEPLETION; REVIEW; THROMBOEMBOLISM; THROMBOGENESIS;

EID: 0037249459     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613536     Document Type: Review

References (43)

1. Fenton JW, II, Olson TA, Zabinski PM, Wilner GD. Anion-binding exosite of human α-thrombin and fibrin(ogen) recognition. Biochemistry 1988; 27: 7106-12.
2. Stubbs MT, Bode W. A player of many parts: The spotlight falls on thrombin's structure. Thromb Res 1993; 69: 1-58.
3. Seegers WH, Nieft M, Loomis EC. Note on the adsorption of thrombin on fibrin. Science 1945; 101: 520-1.
4. Seegers WH. Multiple protein interactions as exhibited by the blood-clotting mechanism. J Phys Colloid Chem 1947; 51: 198-206.
5. Seegers WH, Johnson JF, Fell C. An anti-thrombin reaction related to prothrombin activation. Am J Physiol 1954; 176: 97-103.
6. Liu CY, Nossel HL, Kaplan KL. Defective thrombin binding by abnormal fibrin associated with recurrent thrombosis. Thromb Haemost 1979; 42: 79 (abs).
7. Meh DA, Siebenlist KR, Mosesson MW. Identification and characterization of the thrombin binding sites on fibrin. J Biol Chem 1996; 271: 23121-5.
8. Mosesson MW, Finlayson JS, Umfleet RA. Human fibrinogen heterogeneities. III. Identification of γ chain variants. J Biol Chem 1972; 247: 5223-7.
9. Wolfenstein-Todel C, Mosesson MW. Carboxy-terminal amino acid sequence of a human fibrinogen γ chain variant (γ′). Biochemistry 1981; 20: 6146-9.
10. Kloczewiak M, Timmons S, Lukas TJ, Hawiger J. Platelet receptor recognition site on human fibrinogen. Synthesis and structure-function relationship of peptides corresponding to the C-terminal segment of the γ chain. Biochemistry 1984; 23: 1767-74.
11. Vali Z, Scheraga HA. Localization of the binding site on fibrin for the secondary binding site of thrombin. Biochemistry 1988; 27: 1956-63.
12. Siebenlist KR, DiOrio JP, Budzynski AZ., Mosesson MW. The polymerization and thrombin-binding properties of des-(B beta 1-42)-fibrin. J Biol Chem 1990; 265: 18650-5.
13. Binnie CG, Lord ST. A synthetic analog of fibrinogen α27-50 is an inhibitor of thrombin. Thromb Haemost 1991; 65: 165-8.
14. Meh DA, Siebenlist KR, Brennan SO, Holyst T, Mosesson MW. The amino acid sequences in fibrin responsible for high affinity thrombin binding. Thromb Haemost 2001; 85: 470-4.
15. Meh DA, Mosesson MW, Siebenlist KR, Simpson-Haidaris PJ, Brennan SO, DiOrio JP, Thompson K, Di Minno G. Fibrinogen Naples I (Bβ A68T) non-substrate thrombin binding capacities. Thromb Res 2001; 103; 63-73.
16. Koopman J, Haverkate F, Lord ST, Grimbergen J, Mannucci PM. Molecular basis of fibrinogen Naples associated with defective thrombin binding and thrombophilia. J Clin Invest 1992; 90: 238-44.
17. Farrell DH, Lovely RS, Moaddel M, Stafford AR, Weitz JI. Fibrinogen γ′ chain binds thrombi exosite II. Blood 2000; 96: 448a-9a.
18. Francis CW, Kraus DH, Marder VJ. Structural and chromatographic heterogeneity of normal plasma fibrinogen associated with the presence of three gamma-chain types with distinct molecular weights. Biochim Biophys Acta 1983; 744: 155-64.
19. Francis CW, Keele EM, Marder VJ. Purification of three gamma-chains with different molecular weights from normal human plasma fibrinogen. Biochim Biophys Acta 1984; 797: 328-35.
20. Francis CW, Muller E, Henschen A, Simpson PJ, Marder VJ. Carboxy-terminal amino acid sequences of two large variant forms of the human plasma fibrinogen γ chain. Proc Natl Acad Sci USA 1988; 85: 3358-62.
21. Shariat-Madar Z, Mahdi F, Schmaier AH. Identification and characterization of prolylcarboxypeptidase as an endothelial cell pre-kallikrein activator. J Biol Chem 2002; 277: 17962-9.
22. Liu CY, Nossel HY, Kaplan KL. The biding of thrombin by fibrin. J Biol Chem 1979; 254: 10421-5.
23. De Bosch NB, Mosesson MW, Ruiz-Sáez A, Echenagucia M, Rodriguez-Lemoin A. Inhibition of thrombin generation in plasma by fibrin formation (Antithrombin I). Thromb Haemost 2002; 88: 253-8.
24. Kumar R, Béguin S, Hemker C. The influence of fibrinogen and fibrin on thrombin generation - Evidence for feedback activation of the clotting system by clot bound thrombin. Thromb Haemost 1994; 72: 713-21.
25. Nossel HL, Ti M, Kaplan KL, Spanondis K, Soland T, Butler VP Jr. The generation of fibrinopeptide A in clinical blood samples. Evidence for thrombin activity. J Clin Invest 1976; 58: 1136-44.
26. Francis CW, Markham RE, Barlow GH, Florack TM, Dobrzynski DM, Marder VJ. Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J Lab Clin Med 1983; 102: 220-30.
27. Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood 1988; 72: 616-20.
28. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91.
29. Mutch NJ, Robbie LA, Booth NA. Human thrombi contain an abundance of active thrombin. Thromb Haemost 2001; 86: 1028-34.
30. Di Minno G, Martinez J, Cirillo F, Cerbone AM, Silver MJ, Colucci M, Margaglione M, Tauro R, Semeraro N, Quattrone A, Mancini M. A role for platelets and thrombin in the juvenile stroke of two siblings with defective thrombin-absorbing capacity of fibrin(ogen). Arterioscl Thromb 1991; 11: 785-96.
31. Caen J, Faur Y, Inceman S, Chassigneux J, Seligmann M, Anagnostopoulos T, Bernard J. Nécrose ischémique bilatérale dans un cas de grande hypofibrinogénémie congénitale. Nouv Rev Fr Hématol 1964; 4: 321-6.
32. Marchal G, Duhamel G, Samama M, Flandrin G. Thrombose massive des vaisseaux d'un membre au cours d'une hypofibrinémie congénitale. Hémostase 1964; 4: 81-9.
33. Nilsson IM, Niléhn J-E, Cronberg S, Nordén G. Hypofibrinogenemia and massive thrombosis. Acta Medica Scandinavica 1966; 180: 65-76.
34. Ingram GI, McBrien DJ, Spencer H. Fatal pulmonary embolism in congenital fibrinopenia. Acta Haematol 1966; 35: 56-62.
35. Mackinnon HH, Fekete JF. Congenital afibrinogenemia: Vascular changes and multiple thrombosis induced by fibrinogen infusions and contraceptive medication. Can Med Assoc J 1971; 140: 597-9.
36. Cronin C, Fitzpatrick D, Temperly I. Multiple pulmonary emboli in a patient with afibrinogenaemia. Acta Haematol 1988; 7: 53-4.
37. Drai E, Taillan B, Schneider S, Ferrari E, Bayle J, Dujardin P. Thrombose portale révélatrice d'une afibrinogénémie congénitale. La Presse Médicale 1992; 21: 1820-1.
38. Chafa O, Chellali T, Sternberg C, Reghis A, Hamladji RM, Fischer AM. Severe hypofibrinogenemia associated with bilateral ischemic necrosis of toes and fingers. Blood Coagul Fibrinolysis 1995; 6: 549-52.
39. Dupuy E, Soria C, Molho P, Zini J-M, Rosenstingl S, Laurian C, Bruneval P, Tobelem G. Embolized ischemic lesions of toes in an afibrinogenemic patient: Possible relevance to in vivo circulating thrombin. Thromb Res 2001; 102: 211-9.
40. De Bosch N, Sáez A, Soria C, Soria J, Echenagucia M. Coagulation profile in afibrinogenemia. Thromb Haemost 1997; Suppl: 625 (abs).
41. Korte W, Feldges A. Increased prothrombin activation in a patient with congenital afibrinogenemia is reversible by fibrinogen substitution. Clin Invest 1994; 72: 396-8.
42. Ni H, Denis CV, Subbarao S, Degen JL, Sato TN, Hynes RO, Wagner DD. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest 2000; 106: 385-92.
43. Yang Z, Mochalkin I, Doolittle RF. A model of fibrin formation based on crystal structures of fibrinogen and fibrin fragments complexed with synthetic peptides. Proc Natl Acad Sci USA 2000; 97: 14156-61.